Diagnostic Utility and Cost Analysis of Sequential TF Immunohistochemistry in Hormone-Immunonegative Pituitary Adenomas
Endocrine Oncology · 11.11.2026
DOI: 10.1530/eo-26-0018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 11.11.2026. Verfasst von Yeung-Ae Park und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes & Endocrinology, Royal Melbourne Hospital, Parkville , Victoria, Australia. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To identify the routine use of all pituitary transcription factor (TF) immunohistochemistry (IHC) for pituitary adenoma diagnosis in Australia and New Zealand. To evaluate the diagnostic utility and cost analysis of selective sequential TF IHC, with SF1, followed by TPIT only if SF1-negative, and PIT1 only if SF1-and-TPIT-negative, in hormone-immunonegative pituitary adenomas.
Design
Prospective telephone survey and retrospective cohort study.
Methods
The pathology laboratories of pituitary centres in Australia and New Zealand were surveyed regarding their routine use of TF IHC. At a high-volume pituitary centre in Melbourne, Australia, all three TF IHC were retrospectively applied to the latest 94 labelled null cell adenomas (NCA) diagnosed before routine TF IHC use. Diagnostic efficacy and cost analysis of the simulated selective sequential TF IHC were evaluated compared to universal TF IHC testing. A cohort of 397 hormone-immunonegative pituitary adenomas from Tübingen, Germany, served as an independent validation cohort.
Results
Only 57.1% of pituitary centres in Australia and New Zealand performed routine TF IHC. Of the 94 NCAs, TF IHC revised the diagnosis to SF1-lineage (68.1%), TPIT-lineage (18.1%), and PIT1-lineage adenomas (1.1%). There were no pituitary adenomas with multiple lineages. The simulated selective sequential TF IHC achieved >99% diagnostic accuracy in both Melbourne and Tübingen cohorts, reducing costs by 51.4% (Melbourne) and 63.6% (Tübingen) compared with universal TF IHC.
Conclusions
Although misclassification of pituitary adenomas with multiple lineages is possible, our selective sequential TF IHC approach may offer pragmatic, economical hormone-immunonegative pituitary adenoma classification where TF IHC is not standard practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diabetes & Endocrinology, Royal Melbourne Hospital, Parkville , Victoria, Australia.
- Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville , Victoria, Australia.
- Peter MacCallum Cancer Centre, Parkville , Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville , Victoria, Australia.
- Department of Pathology, Royal Melbourne Hospital, Parkville , Victoria, Australia.
- Colonial Foundation Diagnostics Centre, Walter and Eliza Hall Institute, Parkville , Victoria, Australia.
ORCID-Profile: Yeung-Ae Park
Zitieren
APA
Park, Y. A., Christie, M., Lachman, S., Nasi-Kordhishti, I., Schittenhelm, J., Shen, A., King, J., Trigos, A. S., Zhao, Y., Fourlanos, S., & Yates, C. J. (2026). Diagnostic Utility and Cost Analysis of Sequential TF Immunohistochemistry in Hormone-Immunonegative Pituitary Adenomas. Endocrine Oncology. https://doi.org/10.1530/eo-26-0018
Vancouver
Park YA, Christie M, Lachman S, Nasi-Kordhishti I, Schittenhelm J, Shen A, et al. Diagnostic Utility and Cost Analysis of Sequential TF Immunohistochemistry in Hormone-Immunonegative Pituitary Adenomas. Endocrine Oncology. 2026. doi:10.1530/eo-26-0018
BibTeX
@article{Park2026,
author = {Park, Yeung-Ae and Christie, Michael and Lachman, Sabrina and Nasi-Kordhishti, Isabella and Schittenhelm, Jens and Shen, Angeline and King, James and Trigos, Anna S and Zhao, Yi and Fourlanos, Spiros and Yates, Christopher J},
title = {Diagnostic Utility and Cost Analysis of Sequential TF Immunohistochemistry in Hormone-Immunonegative Pituitary Adenomas},
journal = {Endocrine Oncology},
year = {2026},
doi = {10.1530/eo-26-0018}
}
EUVIMED